薬物誘発性肝炎の後に,持続性放出ニアシンによる結晶ニアシンとの再挑戦
Y Henkin1, K C Johnson, J P Segrest
1Department of Medicine, University of Alabama, Birmingham.
JAMA
|July 11, 1990
まとめ
持続放出ニアシンは,結晶ニアシンよりも肝毒性があります. ある研究では,持続性放出ニアシンによる肝炎の患者は,結晶型ニアシンを肝臓損傷なしに耐えており,結晶型がより安全である可能性を示唆しています.
科学分野:
- 肝臓病理学 肝臓病理学
- 薬理学 薬理学とは
- 内科内科は,内科の内科である.
背景:
- ナイアシン (ニコチン酸) は,結晶および持続放出 (SR) 製剤で利用可能なビタミンです.
- SRナイアシンは,結晶ナイアシンと比較して,肝毒性の増加と関連しています.
研究 の 目的:
- 持続性放出ニアシンと結晶性ニアシンの比較性肝毒性を調査する.
- 結晶ニアシンの安全性を評価するために,SRニアシンによる肝損傷を経験した患者.
主な方法:
- SRナイアシン治療中に肝炎を発症した3人の患者のケーススタディ.
- 同等またはより高い量の結晶ニアシンで再挑戦します.
- 再発性肝細胞損傷の証拠のモニタリング.
主要な成果:
- 患者は,結晶ニアシンリチャレンジを容認し,肝臓損傷が再発しなかった.
- 結晶ニアシンへの切り替え後,肝細胞損傷の証拠は観察されなかった.
結論:
- 結晶ニアシンは,特定の患者の場合,持続性放出ニアシンよりも肝毒性が低い可能性があります.
- これらの発見は,ナイアシン製剤の異なる安全性プロファイルに関する以前の観察を裏付けている.
- ナイアシン誘発性肝炎のメカニズムに関するさらなる研究が必要である.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Phase I Reactions: Reductive Reactions
Phase I biotransformation reductive reactions are chemical processes that modify drugs by introducing or revealing polar functional groups via reduction. Enzymes called reductases catalyze these reactions, playing a pivotal role in drug metabolism by transforming lipophilic drugs into more polar, water-soluble metabolites for easy excretion. An essential type of reductive reaction is the carbonyl group reduction, where aldehydes and ketones are reduced to alcohols. An example is the...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...


